Hims & Hers website

Hims & Hers investors run for the hills despite earnings beat and cheery outlook

Hims & Hers outlook and earnings weren’t enough to quell investors’ fears.

2/24/25 5:02PM

Hims & Hers Health, the tele-pharmacy known for selling copycat versions of popular weight-loss drugs, tanked in aftermarket trading despite largely meeting Wall Street expectations and giving upbeat guidance.

The company reported earnings per share of $0.12, edging above the $0.11 analysts polled by FactSet were expecting. It also reported $481.1 million in revenue, compared to the $470.3 million analysts expected.

Hims & Hers said it expected revenue for the first quarter of 2025 to be between $520 million and $540 million, compared to the $497 million analysts had penciled in. This was the fifth straight quarter that Hims & Hers turned a profit, and 2024 marked its full profitable year.

Still, investors sent the company’s stock down more than 15% in after-hours trading.

Investors are likely still spooked by the news that the Food and Drug Administration declared that semaglutide, the active ingredient in Novo Nordisk’s Ozempic and Wegovy, is no longer in a shortage, limiting Hims & Hers’ ability to make copycat versions.

Removing it from the shortage list means Hims & Hers can no longer sell exact copies of the drug; it’s only allowed to if it adjusts the drug. Hims & Hers CEO Andrew Dudum said in a Friday statement that the company plans to continue selling compounded semaglutide in the form of “personalized treatments.”

Hims & Hers said in its letter to shareholders that it can sell “personalized titration schedules and dosage levels that are not essentially copies of commercially available medications” even with a shortage in place.

But in a footnote repeated three times in the letter, the company said the FDA move “could constrain our ability to continue providing access to compounded semaglutide on our platform once our current inventory has been sold.”

The company did not explicitly report how much it made selling weight-loss drugs, which it started doing in May 2024. It did say that revenue from non-GLP-1 drugs was $1.2 billion of the $1.4 billion it brought in 2024, suggesting it sold roughly $200 million in copycat weight-loss drugs last year.

Luke Kawa

7/13/26

Meet the newly public, Bezos-backed company that’s recreating the sun and stars

General Fusion CEO Greg Twinney spoke with Sherwood News from the Nasdaq during the stock’s first day of trading.

J. Edward Moreno7/7/26

SpaceX gets a wave of bullish ratings from Wall Street analysts

SpaceX received more than a dozen positive analyst calls on Tuesday — including from major Wall Street banks — as they initiate coverage on Elon Musk’s space and AI company.

SpaceX went public on June 12 at a $2.2 trillion valuation, the largest debut in history. While the company hasn’t yet posted a profit, it seems to have convinced Wall Street that it will get there and grow its valuation on the way.

Of the at least 17 analysts that gave a rating on Tuesday, all but one gave it a “buy” or “outperform” rating. MoffettNathanson was "neutral."

The ratings come as SpaceX joined the Nasdaq 100 index, a benchmark tech-heavy basket of companies that underpins millions of portfolios. The inclusion adds built-in demand for the stock from index funds and ETFs.

Still, SpaceX fell more than 5% on Tuesday amid a broader sell-off, and is currently effectively flat from its opening price of $150 a share.

Luke Kawa

7/2/26

US job growth falls far short of estimates in June; unemployment rate unexpectedly dips to 4.2%

Job growth was 57,000. Analysts foresaw job growth of 113,000; prediction markets were more optimistic, looking for job growth above 125,000 but below 150,000.

Floridians Seek Employment Opportunities At Job Fair In Sunrise

Luke Kawa

7/1/26

Meta surges on report it’s starting a cloud business to sell excess AI compute

The story of the hyperscalers in 2026 has largely been “the beatings will continue until the cash flow outlook improves;” this could help change the story for Meta. Or not.

Meta CEO Mark Zuckerberg visits U.S. Capitol for Senate meetings

Paige Oamek6/30/26

Nike sinks to lowest level since 2014 after warning of “challenged” sales environment in Q4 report

Did Nike do it?

Investors had a mixed reaction after the global sports apparel company reported its fourth quarter earnings on Tuesday after the bell. Shares initially rose 5% as Nike beat out Wall Street expectations amid a hefty tariff refund bonus. However, the stock then sank to its lowest level since August 2014 in postmarket trading.

Here are the Q4 numbers:

Revenue of $11.0 billion (estimate: $10.8 billion).
Adjusted earnings per share of $0.20 (estimate: $0.12).

Ahead of this report, Nike warned that results would be flattered by a one-time tariff refund (now estimated at roughly $0.52 per share for the bottom line). That gave the company an extra cushion in snapping its streak of seven quarters of year-over-year profit declines.

Over the past year, the company had been punished by tariffs on imported goods, stagnant consumer spending, and increasing competition from other footwear brands like New Balance, Adidas, and Hoka.

Outgoing CFO Matthew Friend deemed it an “increasingly challenging operating environment, where sell-through remains challenged.”

Hims & Hers investors run for the hills despite earnings beat and cheery outlook

More Markets

SpaceX gets a wave of bullish ratings from Wall Street analysts

Nike sinks to lowest level since 2014 after warning of “challenged” sales environment in Q4 report

Latest Stories